Reclaim your health through regenerative medicine

Whom are Innovacell's cell therapies intended for?

Innovacell develops cell therapies for patients who suffer from bladder weakness or involuntary stool loss due to damage or weakening of the responsible sphincter.

The cell therapies ICEF15 for treating fecal incontinence (urge incontinence) and ICES13 for treating stress urinary incontinence are at an advanced stage of clinical development (phase III). These therapies are currently only available in clinical trials. ICEF16 for treating fecal incontinence (passive incontinence) is in pre-clinical development.

Therapy process

How does the therapy work?

Cell therapy is a therapeutic approach in regenerative medicine. Living cells are administered as an active substance in order to bring about the necessary regeneration in the body. Even a damaged or weakened muscle can be regenerated using cell therapy.

Incontinence is most commonly caused by damage or weakening of a sphincter muscle. To treat this disease, we are developing innovative cell therapies that are designed to regenerate the affected muscles.
This therapy is based on the natural process of muscle formation:

  • A small amount of healthy muscle tissue is removed from the side of the patient’s chest muscle. Muscle stem cells are isolated from this tissue.
  • These muscle stem cells are activated and the resulting muscle precursor cells are multiplied in order to achieve the therapeutically effective number of cells.
  • Cells produced in this way are injected into the affected sphincter using a gentle, minimally invasive procedure and are intended to start the regeneration process in situ. They have the potential to generate new, mature muscle cells and/or connect to existing muscle cells. This is intended to restore the sphincter’s functionality and treat bladder weakness or involuntary stool loss.

Safety of autologous cell therapy with ICEF15 and ICES13

Effectiveness and safety

Clinical testing is ongoing to demonstrate both the safety and efficacy of our cell therapies. Due to the use of autologous cells, our therapies can be considered to be comparatively low risk. Results from clinical studies to date indicate these medicines are safe and well tolerated.

Cell therapy for incontinence

Frequently asked questions

ICES13 for treating stress urinary incontinence is at an advanced stage of clinical development. If you want to take part in a clinical study, contact the doctor treating you.

ICEF15 for treating fecal incontinence (urge incontinence) is at an advanced stage of clinical development. If you want to take part in a clinical study, contact the doctor treating you or find further information here.

ICES13 is being developed for treating stress urinary incontinence. ICEF15 and ICEF16 are intended for treating involuntary stool loss (urge incontinence or passive incontinence).

Clinical testing is ongoing to demonstrate both the safety and efficacy s. Due to the use of autologous cells, our therapies can be considered to be comparatively low risk . Results from clinical studies to date indicate these medicines are safe and well tolerated.

Treatments in the context of clinical studies are free of charge for patients.

Cell therapies ICEF15 for treating fecal incontinence (urge incontinence) and ICES13 for treating stress urinary incontinence are at an advanced stage of clinical development (phase III). ICEF16 for treating fecal incontinence (passive incontinence) is in pre-clinical development.

These medicines will be placed on the market as soon as the necessary clinical trials have been successfully completed and marketing authorization granted. The first registration will probably take place in Japan.